Oncology expansion Daiichi Sankyo Japan is actively strengthening its oncology leadership with new leadership appointments and a push toward a globally integrated commercialization unit, signaling intensified focus on US and European markets as well as potential for co-developed therapies and regional launches.

Strategic partnerships Recent and upcoming collaborations with Mika Health and Innovent Biologics indicate openness to AI-enabled therapeutics and China market access, suggesting sales opportunities for digital health integrations, data-driven patient support, and localized commercialization efforts.

Antibody-drug conjugate Enhertu and related ADC platforms co-developed with AstraZeneca remain a core growth driver, presenting opportunities for cross-market licensing, patient access programs, and expanded indication exploration to drive downstream revenue in oncology portfolios.

Global market entry Brazil launch of Datroway signals ongoing international expansion beyond major markets, highlighting potential for new country-level sales strategies, local partnerships, and regulatory-focused support services for faster market penetration.

Digital and data readiness Adoption of SAP SuccessFactors, Power Platform, OneTrust, and data tools suggests a foundation for scalable commercial operations, enabling targeted account-based marketing, payer engagement, and streamlined compliance for global product launches.